Novo Nordisk stock price forecast: $43.00 resistance as NVO gains 4.74% on news flow

Traders Union
All News
Financial News
Novo Nordisk jumps 4.74% on FDA catalyst

Highlights

FDA's proposed removal of semaglutide from the 503B bulk list is set to strengthen Novo Nordisk’s market exclusivity for Ozempic and Wegovy.
Novo Nordisk reports robust 2025 guidance with $43.27 billion in projected net sales, a $2.1 billion buyback, and plans for a higher dividend.
Technicals show NVO remains bullish above key supports with overbought conditions signaling likely sideways consolidation between $41.00 and $43.00 near-term.

Market exclusivity boosted as FDA considers restricting compounding rivals

The main catalyst for Novo Nordisk’s move is the US Food and Drug Administration’s proposal to remove semaglutide and other actives from its 503B bulk substances list, a change that would restrict compounding pharmacies from producing lower-cost versions of leading brands Ozempic and Wegovy. This regulatory momentum is expected to reinforce Novo Nordisk’s market exclusivity for its flagship diabetes and weight-loss products, concentrating supply and lifting medium-term revenue prospects. Additional support comes from the publication of positive Phase 3 results for the hemophilia A therapy Denecimig, robust 2025 net sales of $43.27 billion and operating profit of $17.88 billion, and a suite of shareholder return actions, including a proposed higher dividend and a $2.1 billion share buyback.

Overbought signals emerge as momentum faces long-term resistance

NVO opened with a notable gap up from $40.29 to $41.85 and now trades close to the intraday high of $42.85, reflecting heightened volatility. The SMA-20 stands at $39.31 and the SMA-50 at $38.73, both comfortably below the current price, while the SMA-200 remains higher at $50.19 and continues to act as long-term resistance. Immediate support is defined by the Ichimoku Kijun at $38.98, just below current levels. Daily technicals reveal strong positive momentum, with a MACD 'Buy' signal, neutral but modest ADX, and several oscillators in overbought territory: RSI at 62.81, CCI at 133.46, and Stoch RSI nearly at its upper limit (99.98). BBP is deeply positive and flagged 'Overbought', while the Awesome Oscillator confirms intraday bullish tone. The confluence of these overstretched indicators against a backdrop of aggressive buying may flag the risk of a near-term pullback, despite the short-term strength.

Retracement risk rises as overextension challenges further upside

For the coming week, NVO is expected to trade within a volatility band between $41.00 and $43.00 relative to current levels. The probability of sustained price appreciation above this range is low, with extended overbought conditions indicating a higher chance of consolidation or a moderate pullback as recent gains are digested. A bullish scenario could play out if NVO breaks above $43.00 on renewed buying interest, while a move below $41.00 would likely trigger profit-taking and a retest of immediate support areas.

Viktoras Karapetjanc, Traders Union expert, believes Novo Nordisk’s outlook remains fundamentally strong, with regulatory and clinical news driving positive sentiment. He sees the FDA’s latest proposal as a key support for branded drug exclusivity, bolstering future revenues and investor confidence. The robust earnings, dividend, and buyback actions reinforce the stock’s appeal, but short-term overbought signals prompt tactical caution. "With structural growth catalysts in place, I expect Novo Nordisk to consolidate recent gains above $41.00 before resuming its upward trajectory on renewed momentum."

Previously it was reported that policymakers and healthcare providers are pushing for expanded preventive care and more efficient federal payment structures to address rising chronic disease and associated costs. The latest regulatory developments surrounding Novo Nordisk’s market exclusivity, alongside strong technical positioning, now add a distinct catalyst to the company’s outlook—traders should closely watch for a decisive break above $43.00, which could trigger the next phase of directional momentum.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.